Showing 2261-2270 of 7009 results for "".
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
https://reachmd.com/programs/cme/optimizing-the-role-for-corticosteroids-within-the-evolving-dmd-treatment-landscape/37232/Navigate corticosteroid use in DMD: Compare options, manage side effects, and align treatment with advanced therapies.From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
https://reachmd.com/programs/cme/from-late-line-rescue-to-early-line-option-the-potential-for-bispecific-antibodies-in-multiple-myeloma/49264/Explore how bispecific antibodies are moving earlier in the treatment paradigm of multiple myeloma, supported by pivotal data showing improved patient outcomes.Beyond Cognition: Managing Alzheimer’s as an Integrated Neurodegenerative–Neuropsychiatric Syndrome
https://reachmd.com/programs/cme/Beyond-Cognition-Managing-Alzheimers-as-an-Integrated-Neurodegenerative-Neuropsychiatric-Syndrome/54842/Examine integrated neurodegenerative and neuropsychiatric features of Alzheimer’s disease, including NPS biology and therapeutic strategies.Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
https://reachmd.com/programs/cme/rapid-data-pulses-from-asco-2026-emerging-data-on-oral-targeted-strategies-in-breast-cancer/57119/Watch our experts review key ASCO 2026 data on oral SERD therapies in breast cancer and discuss the potential impact on treatment sequencing and patient care.Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
https://reachmd.com/programs/cme/Making-the-Right-Moves-in-Metastatic-CSPC-Intensification-Imaging-and-Impact/56687/Experts discuss ADT intensification strategies, trial evidence, and patient selection for doublet and triplet therapy in metastatic CSPC.Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
https://reachmd.com/programs/cme/living-with-systemic-mastocytosis-bridging-clinical-decisions-and-patient-realities/54389/Join us to explore the disease burden of systemic mastocytosis, evidence-based personalized care, and using multidisciplinary strategies to improve outcomes.Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
https://reachmd.com/programs/cme/breaking-the-line-moving-bispecific-antibodies-upstream-in-treating-multiple-myeloma/49265/Learn how early-line bispecific antibodies are reshaping multiple myeloma treatment, supported by emerging efficacy and safety data from key clinical trials.IBD Masterclass: Foundations of Pathophysiology and Targeted Therapy
https://reachmd.com/programs/cme/ibd-masterclass-foundations-of-pathophysiology-and-targeted-therapy/49149/Examine the biological mechanisms underlying IBD, including genetic, microbial, environmental, and immune pathways that inform therapeutic targets.The Future of HNSCC: Aligning Teams, Transforming Care
https://reachmd.com/programs/cme/The-Future-of-HNSCC-Aligning-Teams-Transforming-Care/54394/Practice-changing data in resectable HNSCC? Experts unpack KEYNOTE-689, NIVOPOSTOP, and how to implement perioperative immunotherapy.Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
https://reachmd.com/programs/cme/advancing-care-in-hnscc-evolving-strategies-across-the-disease-continuum/48999/Experts explain how emerging clinical data and novel therapeutic strategies in HNSCC can expand our treatment armamentarium and improve patient outcomes.